Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Value of Maternal Serum Pentraxin 3 (PTX 3) and Heparin-binding Protein (HBP) for Chorioamnionitis in Preterm Premature Rupture of Membranes

NCT05207800 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Wenzhou Medical University as lead sponsor.

NCT NCT05207800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05207800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Value of Maternal Serum Pentraxin 3 (PTX 3) and Heparin-binding Protein (HBP) for Chorioamnionitis in Preterm Premature Rupture of Membranes
Lead sponsor
Second Affiliated Hospital of Wenzhou Medical University
Phase
Observational
Overall status
Unknown status
Start date
February 10, 2022
Completion date
July 31, 2023
Enrollment
180 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

preterm premature rupture of membrane